Late adverse events to iodinated contrast media in patients treated with IL-2: a safety report from the Danish Renal Carcinoma Group (DaRenCa) study – 1

Aska Drljevic-Nielsen; Nikolaj Skou; Jill R. Mains; Erik M. Pedersen; Finn Rasmussen; Frede Donskov

doi:10.1177/02841851231189635

Late adverse events to iodinated contrast media in patients treated with IL-2: a safety report from the Danish Renal Carcinoma Group (DaRenCa) study – 1

Aska Drljevic-Nielsen^*, Nikolaj Skou, Jill R. Mains, Erik M. Pedersen, Finn Rasmussen, Frede Donskov

^*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Tidsskriftartikel › Forskning › peer review

Abstract

Background: A higher incidence of late adverse events (LAEs) to iodinated contrast media in interleukin-2 (IL-2)-treated patients has been reported. Purpose: To assess the incidence of LAEs after administration of iodinated contrast media in patients with metastatic renal cell carcinoma (mRCC) treated with IL-2. Material and Methods: Patients were randomized to treatment with IL-2 and interferon-α with/without bevacizumab in the Danish Renal Carcinoma Group study – 1. Patients underwent a computed tomography (CT) scan at baseline, at one month, at three months, and every third month until RECIST 1.1 defined progression. LAEs due to iodinated contrast media were systematically registered according to the Common Terminology Criteria for Adverse Events classification. Results: In total, 89 patients were included and underwent a total of 507 contrast-enhanced CT scans. An overall incidence of 46 (9.1%) LAEs was observed in 38 of 89 (42.7%) patients; 3 LAEs at baseline (3.4% of all baseline scans), 39 (13.9%) LAEs during IL-2-based therapies, and 4 (2.9%) LAEs after termination of IL-based therapies. There was no difference in progression-free survival, overall survival, and treatment response in patients experiencing LAEs compared to patients without LAEs (P = 0.2, P = 0.5, and P = 0.6, respectively). Conclusion: Patients with mRCC demonstrated a higher incidence of LAEs after administration of iodinated contrast during ongoing IL-2 therapy, indicating that iodinated contrast media may cause a recall phenomenon of IL-2 toxicities in patients with mRCC. Treatment with IL-2 should not be a contraindication for contrast-enhanced scans in patients with mRCC but expertise and vigilance are required.

Originalsprog	Engelsk
Tidsskrift	Acta Radiologica
Vol/bind	64
Nummer	10
Sider (fra-til)	2812-2819
Antal sider	8
ISSN	0284-1851
DOI	https://doi.org/10.1177/02841851231189635
Status	Udgivet - okt. 2023

Adgang til dokumentet

10.1177/02841851231189635

Andre filer og links

Link to publication in Scopus

Citationsformater

@article{54731662fcbc4e1d9f2889debe1f7c22,

title = "Late adverse events to iodinated contrast media in patients treated with IL-2: a safety report from the Danish Renal Carcinoma Group (DaRenCa) study – 1",

abstract = "Background: A higher incidence of late adverse events (LAEs) to iodinated contrast media in interleukin-2 (IL-2)-treated patients has been reported. Purpose: To assess the incidence of LAEs after administration of iodinated contrast media in patients with metastatic renal cell carcinoma (mRCC) treated with IL-2. Material and Methods: Patients were randomized to treatment with IL-2 and interferon-α with/without bevacizumab in the Danish Renal Carcinoma Group study – 1. Patients underwent a computed tomography (CT) scan at baseline, at one month, at three months, and every third month until RECIST 1.1 defined progression. LAEs due to iodinated contrast media were systematically registered according to the Common Terminology Criteria for Adverse Events classification. Results: In total, 89 patients were included and underwent a total of 507 contrast-enhanced CT scans. An overall incidence of 46 (9.1%) LAEs was observed in 38 of 89 (42.7%) patients; 3 LAEs at baseline (3.4% of all baseline scans), 39 (13.9%) LAEs during IL-2-based therapies, and 4 (2.9%) LAEs after termination of IL-based therapies. There was no difference in progression-free survival, overall survival, and treatment response in patients experiencing LAEs compared to patients without LAEs (P = 0.2, P = 0.5, and P = 0.6, respectively). Conclusion: Patients with mRCC demonstrated a higher incidence of LAEs after administration of iodinated contrast during ongoing IL-2 therapy, indicating that iodinated contrast media may cause a recall phenomenon of IL-2 toxicities in patients with mRCC. Treatment with IL-2 should not be a contraindication for contrast-enhanced scans in patients with mRCC but expertise and vigilance are required.",

keywords = "Adverse events, contrast-enhanced computed tomography, IL-2, iodinated contrast media, metastases, renal cell carcinoma",

author = "Aska Drljevic-Nielsen and Nikolaj Skou and Mains, {Jill R.} and Pedersen, {Erik M.} and Finn Rasmussen and Frede Donskov",

note = "Publisher Copyright: {\textcopyright} The Foundation Acta Radiologica 2023.",

year = "2023",

month = oct,

doi = "10.1177/02841851231189635",

language = "English",

volume = "64",

pages = "2812--2819",

journal = "Acta Radiologica ",

issn = "0284-1851",

publisher = "SAGE Publications Ltd",

number = "10",

}

Late adverse events to iodinated contrast media in patients treated with IL-2: a safety report from the Danish Renal Carcinoma Group (DaRenCa) study – 1. / Drljevic-Nielsen, Aska; Skou, Nikolaj; Mains, Jill R. et al.
I: Acta Radiologica , Bind 64, Nr. 10, 10.2023, s. 2812-2819.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Tidsskriftartikel › Forskning › peer review

TY - JOUR

T1 - Late adverse events to iodinated contrast media in patients treated with IL-2

T2 - a safety report from the Danish Renal Carcinoma Group (DaRenCa) study – 1

AU - Drljevic-Nielsen, Aska

AU - Skou, Nikolaj

AU - Mains, Jill R.

AU - Pedersen, Erik M.

AU - Rasmussen, Finn

AU - Donskov, Frede

N1 - Publisher Copyright: © The Foundation Acta Radiologica 2023.

PY - 2023/10

Y1 - 2023/10

N2 - Background: A higher incidence of late adverse events (LAEs) to iodinated contrast media in interleukin-2 (IL-2)-treated patients has been reported. Purpose: To assess the incidence of LAEs after administration of iodinated contrast media in patients with metastatic renal cell carcinoma (mRCC) treated with IL-2. Material and Methods: Patients were randomized to treatment with IL-2 and interferon-α with/without bevacizumab in the Danish Renal Carcinoma Group study – 1. Patients underwent a computed tomography (CT) scan at baseline, at one month, at three months, and every third month until RECIST 1.1 defined progression. LAEs due to iodinated contrast media were systematically registered according to the Common Terminology Criteria for Adverse Events classification. Results: In total, 89 patients were included and underwent a total of 507 contrast-enhanced CT scans. An overall incidence of 46 (9.1%) LAEs was observed in 38 of 89 (42.7%) patients; 3 LAEs at baseline (3.4% of all baseline scans), 39 (13.9%) LAEs during IL-2-based therapies, and 4 (2.9%) LAEs after termination of IL-based therapies. There was no difference in progression-free survival, overall survival, and treatment response in patients experiencing LAEs compared to patients without LAEs (P = 0.2, P = 0.5, and P = 0.6, respectively). Conclusion: Patients with mRCC demonstrated a higher incidence of LAEs after administration of iodinated contrast during ongoing IL-2 therapy, indicating that iodinated contrast media may cause a recall phenomenon of IL-2 toxicities in patients with mRCC. Treatment with IL-2 should not be a contraindication for contrast-enhanced scans in patients with mRCC but expertise and vigilance are required.

AB - Background: A higher incidence of late adverse events (LAEs) to iodinated contrast media in interleukin-2 (IL-2)-treated patients has been reported. Purpose: To assess the incidence of LAEs after administration of iodinated contrast media in patients with metastatic renal cell carcinoma (mRCC) treated with IL-2. Material and Methods: Patients were randomized to treatment with IL-2 and interferon-α with/without bevacizumab in the Danish Renal Carcinoma Group study – 1. Patients underwent a computed tomography (CT) scan at baseline, at one month, at three months, and every third month until RECIST 1.1 defined progression. LAEs due to iodinated contrast media were systematically registered according to the Common Terminology Criteria for Adverse Events classification. Results: In total, 89 patients were included and underwent a total of 507 contrast-enhanced CT scans. An overall incidence of 46 (9.1%) LAEs was observed in 38 of 89 (42.7%) patients; 3 LAEs at baseline (3.4% of all baseline scans), 39 (13.9%) LAEs during IL-2-based therapies, and 4 (2.9%) LAEs after termination of IL-based therapies. There was no difference in progression-free survival, overall survival, and treatment response in patients experiencing LAEs compared to patients without LAEs (P = 0.2, P = 0.5, and P = 0.6, respectively). Conclusion: Patients with mRCC demonstrated a higher incidence of LAEs after administration of iodinated contrast during ongoing IL-2 therapy, indicating that iodinated contrast media may cause a recall phenomenon of IL-2 toxicities in patients with mRCC. Treatment with IL-2 should not be a contraindication for contrast-enhanced scans in patients with mRCC but expertise and vigilance are required.

KW - Adverse events

KW - contrast-enhanced computed tomography

KW - IL-2

KW - iodinated contrast media

KW - metastases

KW - renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85167355009&partnerID=8YFLogxK

U2 - 10.1177/02841851231189635

DO - 10.1177/02841851231189635

M3 - Journal article

C2 - 37545176

AN - SCOPUS:85167355009

SN - 0284-1851

VL - 64

SP - 2812

EP - 2819

JO - Acta Radiologica

JF - Acta Radiologica

IS - 10

ER -

Late adverse events to iodinated contrast media in patients treated with IL-2: a safety report from the Danish Renal Carcinoma Group (DaRenCa) study – 1

Abstract

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater